reports
Abbvie Inc: 1 director
A director at Abbvie Inc sold/sold after exercising options 5,230 shares at 233.560USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...
Regeneron Announces Investor Conference Presentation
Regeneron Announces Investor Conference Presentation TARRYTOWN, N.Y., March 05, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation at the Barclays 28th Annual Global Healthcare Conference at 9:00 a.m. ET on Tuesday, March 10, 2026. The session may be accessed from the "Investors & Media" page of Regeneron's website at . A replay and transcript of the webcast will be archived on the Company's website for at least 30 days. About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commer...
Ciena Corp: 1 director
A director at Ciena Corp sold 2,952 shares at 354.639USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly show...
CPS Announces $50.0 Million Securitization of Residual Interests
CPS Announces $50.0 Million Securitization of Residual Interests LAS VEGAS, Nevada, March 04, 2026 (GLOBE NEWSWIRE) -- Consumer Portfolio Services, Inc. (Nasdaq: CPSS) (“CPS” or the “Company”) today announced the closing of a $50.0 million securitization of residual interests from previously issued securitizations. In the transaction, qualified institutional buyers purchased $50.0 million of asset-backed notes secured by an 80% interest in a CPS majority owned affiliate (“MOA”) that owns the residual interests in four CPS securitizations issued from January 2025 through October 2025. The...
Mckesson Corp: 1 director
A director at Mckesson Corp sold 2,725 shares at 990.000USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
- Dave Nicoski
- Ross LaDuke
Vermilion Compass: Weekly Equity Strategy
Shifting to Neutral Near-Term as Chop Continues We are shifting our near-term outlook to neutral on the S&P 500 (SPX), after being bullish for all but one week since 4/22/25 (we went neutral 11/19/25-11/25/25). Choppy consolidation has continued between support at 6780-6824 and resistance at 7000, and a neutral near-term outlook is appropriate until there is a decisive break in either direction. The Russell 2000 (IWM) remains much more attractive, and we remain constructive near-term on IWM as ...
WM WASTE MANAGEMENT INC.
RGA REINSURANCE GROUP OF AMERICA INCORPORATED
CLH CLEAN HARBORS INC.
ACGL ARCH CAPITAL GROUP LTD.
ABC AMERISOURCEBERGEN CORPORATION
MCK MCKESSON CORPORATION
EFR ENERGY FUELS
CAH CARDINAL HEALTH INC.
RSG REPUBLIC SERVICES INC.
UAMY UNITED STATES ANTIMONY CORP.
MP MP MATERIALS CORP (A)
SPNT SIRIUSPOINT LTD
PPTA PERPETUA RESOURCES CORP
FIHL FIDELIS INSURANCE HOLDINGS LIMITED
CRML CRITICAL METALS CORP.
USAR USA RARE EARTH INC
ALM ALABAMA PWR PFD 5.875%47
Lumentum Holdings Inc: 1 director
A director at Lumentum Holdings Inc sold 5,302 shares at 691.133USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spo...
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a chronic skin disease with underlying type 2 inflammation that can cause debilitating hives and recurring itch in young children TARRYTOWN, N.Y. and PARIS, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and...
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Th...
Regeneron Renews Sponsorship of the Regeneron Science Talent Search Through 2036, Committing an Additional $150 Million to Empower the Next Generation of Science and Technology Leaders Key Takeaways: Regeneron will extend its title sponsorship of the Regeneron Science Talent Search (STS) for a second decade, continuing its partnership with Society for Science to support the United States’ oldest and most prestigious science and mathematics competition for high school seniorsSince the start of Regeneron’s sponsorship in 2017 through this year’s STS, Regeneron and the Society have engaged an...
Moody's Ratings assigns A2 ratings to AbbVie's senior notes; stable ou...
Moody's Ratings (Moody's) assigned A2 ratings to the new senior unsecured notes issuance of AbbVie Inc. ("AbbVie"). There are no changes to AbbVie's existing ratings including the A2 senior unsecured rating and the Prime-1 short-term rating, or the stable outlook. Proceeds of the offering will pri...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TTMI TTM TECHNOLOGIES INC.
PFG PRINCIPAL FINANCIAL GROUP INC.
LGIH LGI HOMES INC.
GTE GRAN TIERRA ENERGY
GOOD GLADSTONE COMMERCIAL CORPORATION
GLW CORNING INC
FAN FABRINET
FIX COMFORT SYSTEMS USA INC.
CUBE CUBESMART
CIEN CIENA CORPORATION
AXTI AXT INC.
AAOI APPLIED OPTOELECTRONICS INC.
COHU COHU INC.
OXM OXFORD INDUSTRIES INC.
RELL RICHARDSON ELECTRONICS LTD.
AEHR AEHR TEST SYSTEMS
UAA UNDER ARMOUR INC. CLASS A
TNDM TANDEM DIABETES CARE
FNKO FUNKO CLASS A
ST SENSATA TECHNOLOGIES HOLDING PLC
VICR VICOR CORP.
ATOM ATOMERA
MMMB MAMAMANCINI'S HOLDINGS INC
STNE STONECO
MRNA MODERNA INC.
ATEX ANTERIX INC
XP XP
PRDO PERDOCEO EDUCATION CORP
JAKK JAKKS PACIFIC INC.
SHLS SHOALS TECHNOLOGIES GROUP
COHR COHERENT CORP
SYRE SPYRE THERAPEUTICS INC.
LGCY LEGACY EDUCATION INC.
HOII REX HOOD GROWTH & INCOME ETF
MDLN MEDLINE INC
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medic...
Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS) Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
ACN ACCENTURE PLC CLASS A
WK WORKIVA
WDAY WORKDAY INC. CLASS A
THRM GENTHERM INCORPORATED
SXT SENSIENT TECHNOLOGIES CORPORATION
SFM SPROUTS FARMERS MARKETS INC.
NSP INSPERITY INC.
HTGC HERCULES CAPITAL INC.
GPC GENUINE PARTS COMPANY
FELE FRANKLIN ELECTRIC CO. INC.
EXTR EXTREME NETWORKS INC.
EXPE EXPEDIA GROUP INC.
CTSH COGNIZANT TECHNOLOGY SOLUTIONS CORPORATION CLASS A
CRY CRYOLIFE INC.
CPRT COPART INC.
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
ATRC ATRICURE INC.
STN. STANTEC INC
TLX TALANX AG
FLTR FLUTTER ENTERTAINMENT PLC
BRO BROWN & BROWN INC.
SLM SLM CORP
TREE LENDINGTREE INC.
USLM U.S. LIME & MINERALS
WCN WASTE CONNECTIONS INC.
GIB.A CGI INC. CLASS A
CHWY CHEWY INC. CLASS A
QS QUANTUMSCAPE
SOFI SOFI TECHNOLOGIES INC
BWMN BOWMAN CONSULTING GROUP LTD
TPG TPG INC
SMR NUSCALE POWER CORP
ALAB ASTERA LABS INC
CAI CARIS LIFE SCIENCES INC
PTRN PATTERN GROUP INC.
LCID LUCID GROUP INC.
GDYN GRID DYNAMICS HOLDINGS INC.
APPE1 ASAN PARDAKHT PERSIAN ORD
Garetosmab Biologics License Application Accepted for FDA Priority Rev...
Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) FOP is an ultra-rare genetic disorder characterized by abnormal bone formation that infiltrates muscles, tendons, ligaments and other connective tissues, resulting in significant disability If approved, garetosmab would be the first and only available treatment shown to reduce the number and volume of new heterotopic bone lesions in adults with FOP TARRYTOWN, N.Y., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) toda...
- Dave Nicoski
- Ross LaDuke
O5Q OWENS CORNING
WHR WHIRLPOOL CORPORATION
CBT CABOT CORPORATION
LNG CHENIERE ENERGY INC.
VC VISTEON CORPORATION
SM SM ENERGY COMPANY
EVEREST RE GROUP LTD.
NWL NEWELL BRANDS INC
LNTH LANTHEUS HOLDINGS INC
KRO KRONOS WORLDWIDE INC.
IOSP INNOSPEC INC.
HY HYSTER-YALE MATERIALS HANDLING INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
DECK DECKERS OUTDOOR CORPORATION
CHH CHOICE HOTELS INTERNATIONAL INC.
BCC BOISE CASCADE CO.
APD AIR PRODUCTS AND CHEMICALS INC.
CHE CHEMED CORPORATION
COLM COLUMBIA SPORTSWEAR COMPANY
TNC TENNANT COMPANY
WSO WATSCO INC.
BXC BLUELINX HOLDINGS
FTV FORTIVE CORP.
BCBP BCB BANCORP INC.
BBWI BATH & BODY WORKS INC
AESI NEW ATLAS HOLDCO INC
BGC BGC GROUP INC
Regeneron Pharmaceuticals Inc: 2 directors
Two Directors at Regeneron Pharmaceuticals Inc sold/sold after exercising options 2,136 shares at between 778.516USD and 778.526USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary tr...
Regeneron Announces Investor Conference Presentations
Regeneron Announces Investor Conference Presentations TARRYTOWN, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows: TD Cowen 46th Annual Health Care Conference at 9:10 a.m. ET on Wednesday, March 4, 2026Leerink Partners 2026 Global Healthcare Conference at 10:40 a.m. ET on Wednesday, March 11, 2026 The sessions may be accessed from the "Investors & Media" page of Regeneron's website at . Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days. About Regen...
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AA...
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy 36 abstracts to be presented across Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies New Dupixent® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in children with atopic dermatitis TARRYTOWN, N.Y., Feb. 10, 2026 (GLOBE NEWSWIR...
Lee Enterprises Reports Strong First Quarter Results and Closing of St...
Lee Enterprises Reports Strong First Quarter Results and Closing of Strategic Investment Q1 Adjusted EBITDA(1) growth of $5M or 61% YOY$50M equity investment(2) enhances financial stabilityInterest rate on outstanding debt reduced to 5% from 9%(3) DAVENPORT, Iowa, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Lee Enterprises, Incorporated (NASDAQ: LEE), a digital-first subscription platform providing high quality, trusted, local news, information and a major platform for advertising in 72 markets, today reported preliminary first quarter fiscal 2026 financial results(4) for the period ended Dece...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.